TB vaccine development: monitoring international patent filings to anticipate access challenges
Maps international patent filings for two late-stage TB vaccine candidates, MTBVAC and M72/AS01E, as well as the QS-21 adjuvant used in M72/AS01E
South Africa
Tuberculosis policy should shift focus to population-level interventions for greatest impact
Uses mathematical modelling to compare the population-level health and economic impacts of TB interventions in Brazil, India and South Africa. It highlights mass vaccination and community-wide screening as interventions with the potential for substantial epidemiological impact.
Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa
The workshop aimed to align stakeholders on priority populations and delivery strategies for future TB vaccines, identify evidence needs to inform national policy decision-making, and outline actions required to ensure timely and equitable introduction.
Anticipating tuberculosis vaccine acceptability in Kenya and South Africa
Assesses willingness to receive a new TB vaccine and explores attitudes, vaccine confidence, hesitancy, information needs and factors influencing potential uptake among adults, adolescents and caregivers in southern Mozambique. The study used surveys and in-depth interviews and found 77% willingness to receive a new TB vaccine among adults and adolescents.
Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa
Examines how a potential new TB vaccine could be introduced in South Africa. Interviews with 26 stakeholders explored implementation priorities, target populations, vaccine price, cost-effectiveness, regulatory approval, financing, procurement, delivery logistics, vaccine acceptability and lessons from existing vaccination programmes.
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies
This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs
Part of Change 2.0
Actionable market intelligence, including vaccine demand forecast/scenarios, generated to strategically guide manufacturers and partners in their planning for introduction in high burden countries. The objectives include: 1. Strategic assessment of appropriate market-shaping interventions, 2.Stakeholder and decision process mapping , 3.Demand dynamics understanding and realistic market forecast development, 4. Commercialization strategy support for lead candidate(s).
IAVI
1. Understand likely use cases, delivery strategies, target populations, and drivers of preference and adoption; 2. Project demand; 3. Evaluate potential willingness to pay and budget impact; 4. Explore innovative financing mechanisms;
Acceptability of and confidence in novel tuberculosis vaccines among adults living with HIV
Objective: Several novel tuberculosis vaccines (NTVs) are being evaluated in clinical trials. Understanding the perception of acceptability and confidence in NTVs will inform implementation strategies. Conclusion: NTV acceptability was high amongst these PWH, and they preferred community-based delivery models. Our findings may inform strategies to increase implementation of NTVs among PWH in South Africa.